{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T18:49:16Z","timestamp":1784054956709,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003065","name":"Universit\u00e4t Wien","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009209","name":"Montana Department of Transportation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009209","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019310","name":"Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019310","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ejphar.2021.173889","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T11:07:18Z","timestamp":1611054438000},"page":"173889","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["T1143 essential for CaV1.2 inhibition by diltiazem"],"prefix":"10.1016","volume":"895","author":[{"given":"Waheed","family":"Shabbir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ejphar.2021.173889_bib1","doi-asserted-by":"crossref","first-page":"6154","DOI":"10.1074\/jbc.274.10.6154","article-title":"Sequence differences between alpha1C and alpha1S Ca2+ channel subunits reveal structural determinants of a guarded and modulated benzothiazepine receptor","volume":"274","author":"Berjukow","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"29","key":"10.1016\/j.ejphar.2021.173889_bib2","doi-asserted-by":"crossref","first-page":"22114","DOI":"10.1074\/jbc.M908836199","article-title":"Molecular mechanism of calcium channel block by isradipine. Role of a drug-induced inactivated channel conformation","volume":"275","author":"Berjukow","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.ejphar.2021.173889_bib3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1021\/jm9605647","article-title":"Diltiazem-like calcium entry blockers: a hypothesis of the receptor-binding site based on a comparative molecular field analysis model","volume":"40","author":"Corelli","year":"1997","journal-title":"J. Med. Chem."},{"issue":"7303","key":"10.1016\/j.ejphar.2021.173889_bib4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nature09153","article-title":"Structural mechanism of C-type inactivation in K(+) channels","volume":"466","author":"Cuello","year":"2010","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ejphar.2021.173889_bib5","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1021\/jm00082a019","article-title":"Benzazepinone calcium channel blockers. 3. Synthesis and structure-activity studies of 3-alkylbenzazepinones","volume":"35","author":"Das","year":"1992","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejphar.2021.173889_bib6","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1124\/mol.64.2.491","article-title":"Molecular determinants of Ca2+ potentiation of diltiazem block and Ca2+-dependent inactivation in the pore region of cav1.2","volume":"64","author":"Dilmac","year":"2003","journal-title":"Mol. Pharmacol."},{"issue":"5","key":"10.1016\/j.ejphar.2021.173889_bib7","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1124\/mol.104.000893","article-title":"Molecular determinants of frequency dependence and Ca2+ potentiation of verapamil block in the pore region of Cav1.2","volume":"66","author":"Dilmac","year":"2004","journal-title":"Mol. Pharmacol."},{"issue":"4873","key":"10.1016\/j.ejphar.2021.173889_bib8","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1126\/science.2458626","article-title":"Sequence and expression of mRNAs encoding the alpha 1 and alpha 2 subunits of a DHP-sensitive calcium channel","volume":"241","author":"Ellis","year":"1988","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.ejphar.2021.173889_bib9","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1021\/jm00082a018","article-title":"Benzazepinone calcium channel blockers. 2. Structure-activity and drug metabolism studies leading to potent antihypertensive agents. Comparison with benzothiazepinones","volume":"35","author":"Floyd","year":"1992","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejphar.2021.173889_bib10","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1073\/pnas.95.4.1903","article-title":"Tagging with green fluorescent protein reveals a distinct subcellular distribution of L-type and non-L-type Ca2+ channels expressed in dysgenic myotubes","volume":"95","author":"Grabner","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.ejphar.2021.173889_bib11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF00656997","article-title":"Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches","volume":"391","author":"Hamill","year":"1981","journal-title":"Pfl\u00fcgers Archiv"},{"issue":"40","key":"10.1016\/j.ejphar.2021.173889_bib12","doi-asserted-by":"crossref","first-page":"24471","DOI":"10.1074\/jbc.271.40.24471","article-title":"Transfer of high sensitivity for benzothiazepines from L-type to class A (BI) calcium channels","volume":"271","author":"Hering","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"24","key":"10.1016\/j.ejphar.2021.173889_bib13","doi-asserted-by":"crossref","first-page":"13323","DOI":"10.1073\/pnas.94.24.13323","article-title":"Molecular mechanism of use-dependent calcium channel block by phenylalkylamines: role of inactivation","volume":"94","author":"Hering","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.ejphar.2021.173889_bib14","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1124\/mol.58.6.1264","article-title":"Molecular determinants of diltiazem block in domains IIIS6 and IVS6 of L-type Ca(2+) channels","volume":"58","author":"Hockerman","year":"2000","journal-title":"Mol. Pharmacol."},{"issue":"30","key":"10.1016\/j.ejphar.2021.173889_bib15","doi-asserted-by":"crossref","first-page":"18759","DOI":"10.1074\/jbc.272.30.18759","article-title":"Molecular determinants of high affinity phenylalkylamine block of L-type calcium channels in transmembrane segment IIIS6 and the pore region of the alpha1 subunit","volume":"272","author":"Hockerman","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"38","key":"10.1016\/j.ejphar.2021.173889_bib16","doi-asserted-by":"crossref","first-page":"22119","DOI":"10.1074\/jbc.270.38.22119","article-title":"Molecular determinants of high affinity phenylalkylamine block of L-type calcium channels","volume":"270","author":"Hockerman","year":"1995","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.ejphar.2021.173889_bib17","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1021\/jm00082a020","article-title":"Benzazepinone calcium channel blockers. 4. Structure-activity overview and intracellular binding site","volume":"35","author":"Kimball","year":"1992","journal-title":"J. Med. Chem."},{"issue":"33","key":"10.1016\/j.ejphar.2021.173889_bib18","doi-asserted-by":"crossref","first-page":"20113","DOI":"10.1074\/jbc.271.33.20113","article-title":"Identification of benz(othi)azepine-binding regions within L-type calcium channel alpha1 subunits","volume":"271","author":"Kraus","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"42","key":"10.1016\/j.ejphar.2021.173889_bib19","doi-asserted-by":"crossref","first-page":"27205","DOI":"10.1074\/jbc.273.42.27205","article-title":"Molecular mechanism of diltiazem interaction with L-type Ca2+ channels","volume":"273","author":"Kraus","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"5911","key":"10.1016\/j.ejphar.2021.173889_bib20","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/302790a0","article-title":"Mechanism of calcium channel blockade by verapamil, D600, diltiazem and nitrendipine in single dialysed heart cells","volume":"302","author":"Lee","year":"1983","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ejphar.2021.173889_bib21","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0006-3495(90)82418-8","article-title":"Limitations of the whole cell patch clamp technique in the control of intracellular concentrations","volume":"58","author":"Mathias","year":"1990","journal-title":"Biophys. J."},{"issue":"14","key":"10.1016\/j.ejphar.2021.173889_bib22","doi-asserted-by":"crossref","first-page":"9409","DOI":"10.1074\/jbc.274.14.9409","article-title":"A region in IVS5 of the human cardiac L-type calcium channel is required for the use-dependent block by phenylalkylamines and benzothiazepines","volume":"274","author":"Motoike","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2021.173889_bib23","doi-asserted-by":"crossref","unstructured":"Shabbir, W., S. Beyl, E. N. Timin, D. Schellmann, T. Erker, A. Hohaus, G. H. Hockerman and S. Hering \"Interaction of diltiazem with an intracellularly accessible binding site on Ca(V)1.2.\" Br. J. Pharmacol. 162(5): 1074-1082.","DOI":"10.1111\/j.1476-5381.2010.01091.x"},{"issue":"8","key":"10.1016\/j.ejphar.2021.173889_bib24","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1161\/hh2001.098983","article-title":"On the role of Ca(2+)- and voltage-dependent inactivation in Ca(v)1.2 sensitivity for the phenylalkylamine (-)gallopamil","volume":"89","author":"Sokolov","year":"2001","journal-title":"Circ. Res."},{"issue":"3","key":"10.1016\/j.ejphar.2021.173889_bib25","doi-asserted-by":"crossref","first-page":"210","DOI":"10.4161\/chan.2.3.6158","article-title":"Structural model of the Ca V 1.2 pore","volume":"2","author":"Stary","year":"2008","journal-title":"Channels"},{"key":"10.1016\/j.ejphar.2021.173889_bib26","article-title":"Structural basis for diltiazem block of a voltage-gated Ca2+ channel","volume":"119","author":"Tang","year":"2019","journal-title":"Mol. Pharmacol.: mol"},{"issue":"25","key":"10.1016\/j.ejphar.2021.173889_bib27","doi-asserted-by":"crossref","first-page":"17594","DOI":"10.1074\/jbc.M800141200","article-title":"Molecular modeling of benzothiazepine binding in the L-type calcium channel","volume":"283","author":"Tikhonov","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.ejphar.2021.173889_bib28","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1089\/154065803770381075","article-title":"Drug targets in the voltage-gated calcium channel family: why some are and some are not","volume":"1","author":"Triggle","year":"2003","journal-title":"Assay Drug Dev. Technol."},{"issue":"4","key":"10.1016\/j.ejphar.2021.173889_bib29","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2174\/138161206775474503","article-title":"L-type calcium channels","volume":"12","author":"Triggle","year":"2006","journal-title":"Curr. Pharmaceut. Des."},{"issue":"1","key":"10.1016\/j.ejphar.2021.173889_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2007.01.016","article-title":"Calcium channel antagonists: clinical uses--past, present and future","volume":"74","author":"Triggle","year":"2007","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"10.1016\/j.ejphar.2021.173889_bib31","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1085\/jgp.85.5.621","article-title":"Interactions of organic calcium channel antagonists with calcium channels in single frog atrial cells","volume":"85","author":"Uehara","year":"1985","journal-title":"J. Gen. Physiol."},{"issue":"12","key":"10.1016\/j.ejphar.2021.173889_bib32","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.amjhyper.2003.09.001","article-title":"Diagnosis of renal artery stenosis: combining gadolinimum-enhanced three-dimensional magnetic resonance angiography with functional magnetic resonance pulse sequences","volume":"16","author":"Zhang","year":"2003","journal-title":"Am. J. Hypertens."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992100042X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992100042X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:46:34Z","timestamp":1757976394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001429992100042X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":32,"alternative-id":["S001429992100042X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.173889","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"T1143 essential for CaV1.2 inhibition by diltiazem","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.173889","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"173889"}}